CEO Succession Plan Xeris Pharmaceuticals is implementing a CEO succession plan with the retirement of Paul Edick in August '24, creating an opportunity to engage with new leadership for potential partnerships or collaborations.
Glucagon Product Development The development of a glucagon product by Xeris Pharmaceuticals in collaboration with Beta Bionics presents a potential sales opportunity for suppliers or partners offering related technologies or services.
Dual-Hormone Pump for Diabetes Xeris Biopharma's collaboration with Beta Bionics to develop a dual-hormone pump for diabetes indicates a focus on innovation, opening avenues for discussions on cutting-edge solutions or joint ventures.
Financing and Revenue Growth Securing $200M in capital and experiencing a significant revenue jump in the last quarter positions Xeris Pharmaceuticals as a financially stable entity, potentially exploring investments or acquisitions in the near future.
Strategic Partnerships Xeris Pharmaceuticals has formed strategic partnerships with companies like Beta Bionics and Regeneron, signaling an openness to collaborations, making it a promising target for businesses looking to expand into the pharmaceutical sector.
Xeris Pharmaceuticals, Inc. uses 8 technology products and services including WordPress, React, Open Graph, and more. Explore Xeris Pharmaceuticals, Inc.'s tech stack below.
| Xeris Pharmaceuticals, Inc. Email Formats | Percentage |
| FLast@xerispharma.com | 96% |
| Last@xerispharma.com | 2% |
| FMiddleLast@xerispharma.com | 1% |
| FiLast@xerispharma.com | 1% |
Pharmaceutical ManufacturingIllinois, United States201-500 Employees
We're a growth-oriented biopharmaceutical company improving patient lives by developing and commercializing advanced products across a range of therapies.
Company Overview
Funding & FinancialsXeris Pharmaceuticals, Inc. has raised a total of $200M of funding over 14 rounds. Their latest funding round was raised on Mar 06, 2024 in the amount of $200M.
Xeris Pharmaceuticals, Inc.'s revenue is in the range of $50M$100M
Funding & FinancialsXeris Pharmaceuticals, Inc. has raised a total of $200M of funding over 14 rounds. Their latest funding round was raised on Mar 06, 2024 in the amount of $200M.
Xeris Pharmaceuticals, Inc.'s revenue is in the range of $50M$100M
Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.
1-888-653-2347 
support@leadiq.com